Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

BioMarin Pharmaceutical Non-GAAP EPS of $0.76 misses by $0.15, revenue of $766M beats by $14.32M (BMRN:NASDAQ)

Summary by Seeking Alpha
BioMarin (BMRN) Q1 results: EPS miss, revenue beat, and raised 2026 revenue guidance to $3.83–$3.93B with GALAFOLD & POMBILITI/OPFOLDA.

1 Articles

Seeking AlphaSeeking Alpha
Lean Right

BioMarin Pharmaceutical Non-GAAP EPS of $0.76 misses by $0.15, revenue of $766M beats by $14.32M (BMRN:NASDAQ)

BioMarin (BMRN) Q1 results: EPS miss, revenue beat, and raised 2026 revenue guidance to $3.83–$3.93B with GALAFOLD & POMBILITI/OPFOLDA.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in United States on Monday, May 4, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Rafael icon

San Rafael

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal